Full-Time

Contracts Manager

Posted on 10/31/2025

StimLabs

StimLabs

51-200 employees

Develops and sells placental tissue therapies

No salary listed

Roswell, GA, USA

Hybrid

Category
Accounting (3)
, ,
Requirements
  • Bachelor’s degree in Business, Management, Healthcare Administration or related field
  • Minimum of 5 years of experience in strategic pricing and contracting is preferred
  • Candidate must be highly organized, detail oriented, able to manage multiple tasks and be an excellent communicator
  • Strong analytical, strategic, and problem-solving skills required
  • Customer-service mindset and skills to support the field sales teams price/contract needs
  • Demonstrated ability to work seamlessly with remote sites and business partners
  • Proficient in the use of Microsoft Word and PowerPoint
  • Highly proficient in the use of Microsoft Excel (e.g. working with large datasets, PivotTables, Arrays, Conditional Formatting, etc)
  • Experience with any or all of the following is preferred: PowerBI, Microsoft Dynamics, and CRMs.
  • Travel required: Less than 10%
Responsibilities
  • Support the Vision, Mission, and Purpose of both StimLabs Corporate Accounts and the Market Access team.
  • Learn and evaluate current processes for all contracting and analytical tasks currently being performed for Corporate Accounts.
  • Prepare and maintain GPO, IDN, Hospital and large practice price file repository.
  • Evaluate, update and prepare all monthly and quarterly price reporting.
  • Create and develop alternative pricing models using excel frameworks to support business strategies and market changes
  • Develop and maintain competitive pricing analytics.
  • Help develop and manage current infrastructure to ensure and control pricing consistency and accuracy across all accounts.
  • Track and manage all contract activity and touch points from initiation through final execution.
  • Participate in redlining business terms and coordinate with legal for contractual review of redlines
  • Execute analysis of net contract sales, market share, and contract pricing
  • Maintain central archives of contracts and all associated documentation
  • Assist in responding to formal RFPs to include customer-specific contract templates, product cross references, special formatting and other required templates. Complete and actively maintain IDN and GPO portals, including initial vendor information forms
  • Develop, maintain and process IDN and GPO required report formats and reporting for Finance
  • Work directly with Corporate Accounts Director to assist with deal assessment and financial evaluation to create analytical deliverables from master financial models
  • Develop internal and competitive product knowledge to support corporate projects and assist in market analysis and pricing strategies.
  • Develop Hospital Market share analysis and statistics to support sales strategy and hiring needs.
  • Develop and maintain tools - dashboards for analyzing growth and contract performance in Hospital IDNs and GPOs
  • Process monthly and quarterly Rebates and Administrative fees in timely manner
  • Work directly with Corporate Accounts to analyze sales, competition, and reimbursement data to develop new tools to help support strategic growth goals within Hospitals, GPOs, IDNs, and large private practice networks
  • Collaborate regularly with the Market Access team, Marketing, Sales Operations, Business Intelligence, Customer Service, Finance, Legal, Compliance, and others to support corporate initiatives on behalf of Corporate Accounts.
Desired Qualifications
  • Minimum of 5 years of experience in strategic pricing and contracting is preferred
  • Experience with PowerBI, Microsoft Dynamics, and CRMs is preferred

StimLabs focuses on developing, producing, and selling placental tissue–based products that support regenerative healing for patients. These products are used by healthcare providers, hospitals, and clinics to help repair damaged tissues. They work by using proprietary processing techniques to prepare placental tissue into medical materials that can be applied to wounds or injured areas to promote tissue regeneration and healing. What sets StimLabs apart from competitors is its ownership of proprietary processing methods and a strong emphasis on regulatory compliance and quality control, which helps ensure safety and reliability for clinicians and patients. The company’s goal is to advance regenerative medicine by providing trusted placental tissue products that improve patient outcomes and become a preferred partner for healthcare providers.

Company Size

51-200

Company Stage

Seed

Total Funding

$10M

Headquarters

Roswell, Georgia

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Advanced wound care market grows from $7.77B in 2024 to $13.04B by 2032.
  • Relese dCHPM allograft improved hard-to-heal wound closure in November 2025 trial.
  • Mölnlycke partners as exclusive provider for CAMPSTIM diabetic ulcer trial.

What critics are saying

  • MiMedx Medicare coverage erodes StimLabs placental product market share.
  • Organogenesis Apligraf blocks Allacor P formulary inclusion with Level 1 evidence.
  • FDA reclassifies amniotic devices as biologics, devaluing StimLabs processing IP.

What makes StimLabs unique

  • Allacor P is first FDA 510(k)-cleared human umbilical cord particulate device.
  • Architect Fx uses proprietary BriDGE technology from equine pericardium.
  • Exclusive US distribution rights for Geistlich's Derma-Gide xenograft.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Flexible Work Hours

Company News

PR Newswire
Mar 3rd, 2026
StimLabs launches Architect Fx collagen matrix for chronic and complex wound treatment

StimLabs, a regenerative medicine company, has launched Architect Fx, an advanced collagen matrix device for wound management derived from equine pericardium. The product received FDA 510(k) clearance for treating chronic diabetic, venous and pressure ulcers, as well as traumatic and surgical wounds. The device uses proprietary BriDGE technology to create a durable extracellular matrix that resists degradation and supports reapplications and extended wear. This allows clinicians to adapt treatment based on wound condition and healing progress. Distribution of Architect Fx began in Q1 2026. The launch supports StimLabs' strategy to expand its commercial footprint and product portfolio in the advanced wound care market, according to Tom Dion, the company's executive vice president and chief commercial officer.

PR Newswire
Feb 12th, 2026
StimLabs gains FDA clearance for DermaForm collagen wound care device

StimLabs, a regenerative medicine company, has received FDA 510(k) clearance for DermaForm, a collagen scaffold particulate wound care device developed with Geistlich. The extracellular matrix product is designed to protect and manage chronic and acute wounds. The clearance strengthens StimLabs' portfolio of wound care solutions. Tom Dion, the company's EVP and chief commercial officer, said DermaForm represents the company's ongoing commitment to innovation and bringing meaningful products to market. StimLabs, which focuses on wound care and surgical applications, developed DermaForm through its collaboration with Geistlich, a Swiss family-owned company and global leader in regenerative medicine. The partnership aims to deliver advanced solutions that enhance outcomes and improve quality of life for patients with complex wounds.

Medical Device Network
Jan 6th, 2026
StimLabs launches Allacor P for acute and chronic wound care

StimLabs launches Allacor P for acute and chronic wound care. Allacor P retains key ECM components, including collagen I and hyaluronic acid. StimLabs has announced the launch of Allacor P, a human umbilical cord device designed for acute and chronic wound management. The device received clearance from the US Food and Drug Administration (FDA) in February 2024 with the hospital solution Corplex P, which is derived from umbilical cord tissue. It claims to be the first graft derived from the human umbilical cord extracellular matrix (ECM) and is indicated for a broad spectrum of wounds. The device features a particulate format that adapts to irregular and complex wound surfaces. Allacor P retains key ECM components, including collagen I and hyaluronic acid. According to Stimlabs, this composition supports the application process across various clinical scenarios. US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. Last year, the product received an A Code, enabling its introduction into additional care sites. Since receiving clearance, StimLabs has focused on building scientific evidence and gathering clinical feedback from real-world use cases to support informed application of the product as it expands into new healthcare settings. StimLabs wound care clinician Dr R Daniel Davis said: "The dehydrated human umbilical cord particulate device has the potential to impact so many patients in the same way it did for a recent complex case of mine. "The dramatic improvement after just one application brought hope to my patient during a challenging time. I'm an advocate for this device; it's something providers need to try." The company's operations are currently centred on regenerative medicine with emphasis on wound care and surgical applications. In November 2025, StimLabs reported findings from a multi-centre trial of its fenestrated dehydrated complete human placental membrane (dCHPM) allograft, Relese, when used alongside standard of care for wounds that are hard to heal.

Medical Device Network
Nov 28th, 2024
Geistlich Pharma partners with StimLabs for wound care distribution in US

Geistlich Pharma has entered an exclusive national distribution collaboration agreement with StimLabs in the US, focusing on the commercialisation of the former's Advanced Wound Matrix, Derma-Gide.

Business Wire
Nov 26th, 2024
Geistlich Announces Exclusive Distribution Partnership for its Leading Wound Care Portfolio in the United States

WOLHUSEN, Switzerland-(BUSINESS WIRE)-Geistlich Pharma AG, a worldwide leader in regenerative technologies, announced an exclusive national distribution partnership agreement with StimLabs of Roswell, GA.

INACTIVE